Intervention Review

Fibrin sealant use for minimising peri-operative allogeneic blood transfusion

  1. Paul A Carless1,*,
  2. David A Henry2,
  3. Danielle M Anthony1

Editorial Group: Cochrane Injuries Group

Published Online: 20 JAN 2003

Assessed as up-to-date: 11 MAR 2008

DOI: 10.1002/14651858.CD004171


How to Cite

Carless PA, Henry DA, Anthony DM. Fibrin sealant use for minimising peri-operative allogeneic blood transfusion. Cochrane Database of Systematic Reviews 2003, Issue 1. Art. No.: CD004171. DOI: 10.1002/14651858.CD004171.

Author Information

  1. 1

    Faculty of Health, University of Newcastle, Discipline of Clinical Pharmacology, Newcastle, New South Wales, Australia

  2. 2

    Institute of Clinical Evaluative Sciences, Toronto, Ontario, Canada

*Paul A Carless, Discipline of Clinical Pharmacology, Faculty of Health, University of Newcastle, Level 5, Clinical Sciences Building, Newcastle Mater Hospital, Edith Street, Waratah, Newcastle, New South Wales, 2298, Australia. Paul.Carless@newcastle.edu.au.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 20 JAN 2003

SEARCH

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Jad Bou Monsef, Johannes Buckup, Wenzel Waldstein, Charles Cornell, Friedrich Boettner, Fibrin sealants or cell saver eliminate the need for autologous blood donation in anemic patients undergoing primary total knee arthroplasty, Archives of Orthopaedic and Trauma Surgery, 2014, 134, 1, 53

    CrossRef

  2. 2
    Torsten Kluba, Katrin Fiedler, Beate Kunze, Ingmar Ipach, Andreas Suckel, Fibrin sealants in orthopaedic surgery: practical experiences derived from use of QUIXIL® in total knee arthroplasty, Archives of Orthopaedic and Trauma Surgery, 2012, 132, 8, 1147

    CrossRef